HUTCHMED shares are trading higher after the company announced entered into an exclusive development and license agreement that granted the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.

Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial

Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application supported by SAFFRON,

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

Reported Sunday, HUTCHMED Doses First Patient In Phase Ia Dose Escalation Of First-In-Class HMPL-A830 To Determine Maximum Tolerated Dose In Advanced Solid Tumors

Reported Earlier, HUTCHMED To Showcase New And Updated Clinical Data From Sponsored And Investigator-Initiated Studies Across Multiple Cancer Types At ESMO Congress 2026, Madrid